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with treatment (P  0.001). Although subjective compli-
ance declined as PEI score declined, the relationship was
not statistically significant. A significant relationship was
found between treatment and PEI score (P  0.05), with
more patients in the candesartan cilexetil group achieving
control with low side-effects and fewer falling into the
high impact category. CONCLUSION: Results suggest
the PEI is a useful summary indicator of the efficacy of a
given agent relative to the patient’s perception of tolera-
bility. Further study of the predictive value of this index
in terms of drug-switching and long-term compliance in
hypertension and the usefulness of this type of system for
other products and indications is warranted.
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BACKGROUND: Rates of patient adherence (compli-
ance) range from as low as 8% to over 100%. Among
factors negatively influencing adherence are multiple daily
dosing (MDD), chronic duration, and asymptomatic dis-
ease. Inconsistent reports suggest single daily dosing
(SDD) may be associated with improved adherence. OB-
JECTIVES: This meta-analysis compared SDD to MDD
and twice daily regimens (BID) with regard to adherence
rates for antihypertensive pharmacotherapy. METH-
ODS: Medline, IPA and Embase searches located com-
parative trials in adults taking oral solid dosage forms. A
random effects model was used to combine and analyze
data. RESULTS: We included eight primary studies in the
analysis, examining 11,485 patients (1830 for SDD,
4405 for BID, 4147 for [BID], and 9655 for all MDD).
The mean rate for SDD  SE (91.4%  2.2%) was sig-
nificantly higher (Z  4.46, P  0.001) than MDD
(83.2%  3.5%). The mean rate for SDD (92.7% 
2.3%) was also significantly higher (Z  2.22, P 
0.026) than BID (87.1%  2.9%). The difference be-
tween BID (90.8%  4.7%) and [BID] (86.3% 
6.7%) was not statistically significant (Z  1.82, P 
0.069). DISCUSSION: This literature-based meta-analy-
sis update confirms our previous findings showing SDD
to be associated with better adherence than both BID and
MDD in hypertension. Consequently, SDD may further
induce a decrease in morbidity, relapse rates, and hospi-
tal admissions. However, those who do not fully adhere
to SDD may present an increased risk of relapse by miss-
ing their daily dose. CONCLUSION: Our meta-analysis
supports the association of once-daily regimens with bet-
ter adherence to antihypertensive pharmacotherapy. Fur-
ther research is warranted to validate findings for other
diseases.
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OBJECTIVE: To assess the effect of polypharmacy on
hospitalization rates in an elderly CHF Medicaid popula-
tion. METHODS: All subjects possessing diagnoses
codes indicative of CHF (ICD9-CM  402.01, 402.11,
428, 402.91, 404.01, 404.02) greater than 59 years of
age at first diagnosis in the South Carolina Medicaid pro-
gram between 1993–1995 were eligible for inclusion.
Subjects were excluded if they resided in a nursing facility
which precluded access to their drug utilization. Poly-
pharmacy was defined as actively taking more than 3.5
prescriptions per day in the first year following the initial
CHF diagnosis. Hospitalization was modeled using logis-
tic regression and time to hospitalization was analyzed
using survival analysis. Propensity score methods were
used to adjust for treatment bias. A subject’s prior year
costs and number of comorbidities were used as surro-
gate controls for severity. RESULTS: A total of 702 sub-
jects met all inclusion criteria. The mean age was 67.35
(SD  8.9) and 79.5% were female. Nearly 58% of sub-
jects were hospitalized in the 2 years following the initial
diagnosis. Polypharmacy was not significantly associated
with hospitalization (OR  1.22, 95%CI 0.72–1.71) or
time to hospitalization (RR  1.042, 95%CI 0.08–1.34).
Increasing number of comorbidities was significantly as-
sociated with hospitalization (OR  1.75, 95%CI 1.26–
2.44) and time to hospitalization (RR  1.16, 95%CI
1.07–1.27). CONCLUSIONS: Polypharmacy does not
appear to affect hospitalization rates in the first year fol-
lowing initial diagnosis. Analysis of the log survival func-
tion plot, however, suggests polypharmacy may increase
the likelihood of hospitalization in the second year.
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Secondary prevention plays a significant role in decreas-
ing recurrent myocardial infarction and cardiovascular
mortality. In reducing patient risk, medication effective-
ness is dependent on patient compliance. OBJECTIVE:
We conducted a retrospective pilot study to assess patient
compliance with aspirin, beta-blocker, ACE inhibitor, and
lipid-lowering therapy approximately two years after an
acute myocardial infarction. METHODS: At the Univer-
sity of Michigan Medical Center, 199 consecutive patients
admitted to the Cardiology service in 1997 and discharged
alive with acute myocardial infarction were prospectively
